^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

mulnitorsen (Andes-1537)

i
Other names: Andes-1537, Andes 1537
Associations
Company:
Andes Biotech
Drug class:
Apoptosis inducer, ncmtRNA interference
Associations
over2years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=67, Completed, Andes Biotechnologies | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
RAS wild-type • NRAS wild-type
|
mulnitorsen (Andes-1537)
almost3years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=67, Active, not recruiting, Andes Biotechnologies | Recruiting --> Active, not recruiting | N=139 --> 67 | Trial completion date: Nov 2022 --> Apr 2022
Enrollment closed • Enrollment change • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
RAS wild-type • NRAS wild-type
|
mulnitorsen (Andes-1537)
3years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=139, Recruiting, Andes Biotechnologies | Trial completion date: Sep 2021 --> Nov 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
RAS wild-type • NRAS wild-type
|
mulnitorsen (Andes-1537)
over3years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=124, Recruiting, Andes Biotechnologies | Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Sep 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
mulnitorsen (Andes-1537)
over4years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=144, Recruiting, Andes Biotechnologies | Active, not recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
mulnitorsen (Andes-1537)
over4years
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov)
P1, N=144, Active, not recruiting, Andes Biotechnologies | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
mulnitorsen (Andes-1537)
over4years
Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors. (PubMed, J Cancer)
Similarly, treatment of a high-grade bladder cancer PDX with Andes-1537S resulted in a strong inhibition of tumor growth. Our results suggest that ASncmtRNAs could be potent targets for bladder cancer as adjuvant therapy.
Journal
|
BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3)
|
mulnitorsen (Andes-1537)